Rachel Paes de Araújo

Dr. Rachel Paes de Araújo

UNIPEX, UNESP - São Paulo State University - Botucatu Medical School, Botucatu, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
VSVanessa G. P. Souza
Vanessa G. P. Souza
RARachel Paes de Araújo
Rachel Paes de Araújo
MSMariana R. Santesso
Mariana R. Santesso
ASAna Laura Seneda
Ana Laura Seneda
Iael Weissberg MinutentagIael Weissberg Minutentag
Iael Weissberg Minutentag
PRPatricia Reis
Patricia Reis
Lung cancer is one of the most frequent tumors that metastasize to the brain. Brain metastasis (BM) is common in advanced cases, being the major cause of patient morbidity and mortality. BMs are thought to arise via the seeding of circulating tumor cells into the brain microvasculature. In brain tissue, the interaction with immune cells promotes a microenvironment favorable to the growth of cancer cells. Despite multimodal treatments and advances in systemic therapies, lung cancer patients still have poor prognoses. Therefore, there is an urgent need to identify the molecular drivers of BM and clinically applicable biomarkers in order to improve disease outcomes and patient survival. The goal of this review is to summarize the current state of knowledge on the mechanisms of the metastatic spread of lung cancer to the brain and how the metastatic spread is influenced by the brain microenvironment, and to elucidate the molecular determinants of brain metastasis regarding the role of genomic and transcriptomic changes, including coding and non-coding RNAs. We also present an overview of the current therapeutics and novel treatment strategies for patients diagnosed with BM from NSCLC.

Verified
Journal Article
Open access
PDF file
VSVanessa G. P. Souza
Vanessa G. P. Souza
AFAisling Forder
Aisling Forder
LBLiam Jerome Brockley
Liam Jerome Brockley
MPMichelle E. Pewarchuk
Michelle E. Pewarchuk
NTNikita Telkar
Nikita Telkar
PRPatricia Reis
Patricia Reis
Liquid biopsies have emerged as a promising tool for the detection of metastases as well as local and regional recurrence in lung cancer. Liquid biopsy tests involve analyzing a patient’s blood, urine, or other body fluids for the detection of biomarkers, including circulating tumor cells or tumor-derived DNA/RNA that have been shed into the bloodstream. Studies have shown that liquid biopsies can detect lung cancer metastases with high accuracy and sensitivity, even before they are visible on imaging scans. Such tests are valuable for early intervention and personalized treatment, aiming to improve patient outcomes. Liquid biopsies are also minimally invasive compared to traditional tissue biopsies, which require the removal of a sample of the tumor for further analysis. This makes liquid biopsies a more convenient and less risky option for patients, particularly those who are not good candidates for invasive procedures due to other medical conditions. While liquid biopsies for lung cancer metastases and relapse are still being developed and validated, they hold great promise for improving the detection and treatment of this deadly disease. Herein, we summarize available and novel approaches to liquid biopsy tests for lung cancer metastases and recurrence detection and describe their applications in clinical practice.

8 December 2023 in Cells
Verified
Journal Article
Open access
PDF file
VSVanessa G. P. Souza
Vanessa G. P. Souza
AFAisling Forder
Aisling Forder
MPMichelle E. Pewarchuk
Michelle E. Pewarchuk
NTNikita Telkar
Nikita Telkar
RARachel Paes de Araújo
Rachel Paes de Araújo
WLWan L. Lam
Wan L. Lam
In recent years, there has been a growing interest in the relationship between microorganisms in the surrounding environment and cancer cells. While the tumor microenvironment predominantly comprises cancer cells, stromal cells, and immune cells, emerging research highlights the significant contributions of microbial cells to tumor development and progression. Although the impact of the gut microbiome on treatment response in lung cancer is well established, recent investigations indicate complex roles of lung microbiota in lung cancer. This article focuses on recent findings on the human lung microbiome and its impacts in cancer development and progression. We delve into the characteristics of the lung microbiome and its influence on lung cancer development. Additionally, we explore the characteristics of the intratumoral microbiome, the metabolic interactions between lung tumor cells, and how microorganism-produced metabolites can contribute to cancer progression. Furthermore, we provide a comprehensive review of the current literature on the lung microbiome and its implications for the metastatic potential of tumor cells. Additionally, this review discusses the potential for therapeutic modulation of the microbiome to establish lung cancer prevention strategies and optimize lung cancer treatment.

1 September 2016 in Cadernos Saúde Coletiva
Verified
Journal Article
Open access
PDF file
RARachel Paes de Araújo
Rachel Paes de Araújo
MNMarli Brito Moreira de Albuquerque Navarro
Marli Brito Moreira de Albuquerque Navarro
TCTelma Abdalla de Oliveira Cardoso
Telma Abdalla de Oliveira Cardoso
Febre maculosa é uma doença infecciosa caracterizada por febre, com formas leves e atípicas até formas graves, e, quando não tratada adequadamente, pode apresentar taxa de letalidade de 85%. Causada pela Rickettsia rickettsii, é transmitida por meio da saliva de carrapato. No Brasil, o vetor mais importante é o Amblyomma cajennense. Discute-se o número de óbitos por Rickettsia no Brasil, projetando a necessidade de ampliação e disseminação do conhecimento sobre a possibilidade de ocorrência da febre maculosa brasileira (FMB), além de debater sintomas, diagnóstico diferencial e dados epidemiológicos. A metodologia consistiu na identificação dos óbitos por Rickettsia no Brasil entre 2005-2010, utilizando-se o Sistema de Informação sobre Mortalidade (SIM). Foram estudados 75 casos. Observou-se taxa de letalidade de 24,8% e uma concentração de óbitos nas regiões Sudeste e Sul do país. Os resultados obtidos contribuem para a sensibilização dos profissionais sobre a necessidade de união dos dados clínicos, epidemiológicos e laboratoriais, facilitando o reconhecimento da doença e o tratamento precoce.

7 March 2019 in Metabolites
Verified
Journal Article
Open access
PDF file
RARachel Paes de Araújo
Rachel Paes de Araújo
NBNatália Bertoni
Natália Bertoni
ASAna Laura Seneda
Ana Laura Seneda
TFTainara F. Felix
Tainara F. Felix
MCMárcio de Carvalho
Márcio de Carvalho
Luis MurLuis Mur
Luis Mur
Metabolomics based on untargeted flow infusion electrospray ionization high-resolution mass spectrometry (FIE-HRMS) can provide a snap-shot of metabolism in living cells. Lung Squamous Cell Carcinoma (SCC) is one of the predominant subtypes of Non-Small Cell Lung Cancers (NSCLCs), which usually shows a poor prognosis. We analysed lung SCC samples and matched histologically normal lung tissues from eight patients. Metabolites were profiled by FIE-HRMS and assessed using t-test and principal component analysis (PCA). Differentially accumulating metabolites were mapped to pathways using the mummichog algorithm in R, and biologically meaningful patterns were indicated by Metabolite Set Enrichment Analysis (MSEA). We identified metabolic rewiring networks, including the suppression of the oxidative pentose pathway and found that the normal tricarboxylic acid (TCA) cycle were decoupled from increases in glycolysis and glutamine reductive carboxylation. Well-established associated effects on nucleotide, amino acid and thiol metabolism were also seen. Novel aspects in SCC tissue were increased in Vitamin B complex cofactors, serotonin and a reduction of γ-aminobutyric acid (GABA). Our results show the value of FIE-HRMS as a high throughput screening method that could be exploited in clinical contexts.

1 April 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
KWKasope Wolffs
Kasope Wolffs
RLRenjiao Li
Renjiao Li
BMBethan Mansfield
Bethan Mansfield
DPDaniel Pass
Daniel Pass
RBRichard T. Bruce
Richard T. Bruce
PYPolina L Yarova
Polina L Yarova
Idiopathic pulmonary fibrosis (IPF) is a disease with a poor prognosis and no curative therapies. Fibroblast activation by transforming growth factor β1 (TGFβ1) and disrupted metabolic pathways, including the arginine–polyamine pathway, play crucial roles in IPF development. Polyamines are agonists of the calcium/cation-sensing receptor (CaSR), activation of which is detrimental for asthma and pulmonary hypertension, but its role in IPF is unknown. To address this question, we evaluated polyamine abundance using metabolomic analysis of IPF patient saliva. Furthermore, we examined CaSR functional expression in human lung fibroblasts (HLFs), assessed the anti-fibrotic effects of a CaSR antagonist, NPS2143, in TGFβ1-activated normal and IPF HLFs by RNA sequencing and immunofluorescence imaging, respectively; and NPS2143 effects on polyamine synthesis in HLFs by immunoassays. Our results demonstrate that polyamine metabolites are increased in IPF patient saliva. Polyamines activate fibroblast CaSR in vitro, elevating intracellular calcium concentration. CaSR inhibition reduced TGFβ1-induced polyamine and pro-fibrotic factor expression in normal and IPF HLFs. TGFβ1 directly stimulated polyamine release by HLFs, an effect that was blocked by NPS2143. This suggests that TGFβ1 promotes CaSR activation through increased polyamine expression, driving a pro-fibrotic response. By halting some polyamine-induced pro-fibrotic changes, CaSR antagonists exhibit disease-modifying potential in IPF onset and development.